909912-09-0

Basic information

• Product Name: 2-AMino-5-benzyloxy-4-Methoxybenzoic acid
• Synonyms: 2-AMino-5-benzyloxy-4-Methoxybenzoic acid
• CAS NO: 909912-09-0
• Molecular Formula: C₁₅H₁₅NO₄
• Molecular Weight: 273.2839
• Mol File: 909912-09-0.mol

Chemical Properties

• Melting Point: 108 °C(Solv: isopropanol (67-63-0))
• Boiling Point: 462.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.283±0.06 g/cm3(Predicted)
• PKA: 2.32±0.10(Predicted)
• CAS DataBase Reference: 2-AMino-5-benzyloxy-4-Methoxybenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMino-5-benzyloxy-4-Methoxybenzoic acid(909912-09-0)
• EPA Substance Registry System: 2-AMino-5-benzyloxy-4-Methoxybenzoic acid(909912-09-0)

Safety Data

• Hazardous Substances Data: 909912-09-0(Hazardous Substances Data)

Usage

General Description

2-Amino-5-benzyloxy-4-methoxybenzoic acid is a chemical compound with the molecular formula C16H15NO4. It is a derivative of benzoic acid and contains both amino and methoxy functional groups. 2-AMino-5-benzyloxy-4-Methoxybenzoic acid is commonly used in organic synthesis and as a building block for the synthesis of various pharmaceuticals and biologically active compounds. It has been studied for its potential pharmacological applications, including anti-inflammatory and anti-cancer properties. Additionally, it has been investigated for its potential role as an antioxidant and in the treatment of certain neurological disorders.

Upstream product

• 855793-63-4 methyl 2-amino-5-(benzyloxy)-4-methoxybenzoate 
• 164161-49-3 methyl 5-(benzyloxy)-4-methoxy-2-nitrobenzoate 
• 215659-03-3 methyl 5-hydroxy-4-methoxy-2-nitrobenzoate 
• 31839-20-0 5-hydroxy-4-methoxy-2-nitrobenzoic acid 
• 4998-07-6 4,5-dimethoxy-2-nitro-benzoic acid 
• 6702-50-7 3-hydroxy-4-methoxybenzoate 
• 57535-57-6 methyl 3-(benzyloxy)-4-methoxy-benzoate 
• 100-39-0 benzyl bromide 
• 634197-80-1 2-amino-5-benzyloxy-4-methoxybenzoic acid benzyl ester 
• 634198-01-9 5-benzyloxy-4-methoxy-2-nitrobenzoic acid benzyl ester 

Downstream Products

• 286371-64-0 6-(benzyloxy)-7-methoxyquinazolin-4(3H)-one 
• 1006890-84-1 6-(benzyloxy)-7-methoxy-3-(2.2,2-trifluoroethyl)quinazolin-4(3H)-one 
• 1006890-01-2 7-methoxy-4-pyridin-3-yl-6-(2-quinolin-2-ylethoxy)quinazoline 
• 1006890-13-6 6-(benzyloxy)-7-methoxy-N,N-dimethylquinazolin-4-amine 
• 1006889-93-5 6-(benzyloxy)-7-methoxy-4-(pyridin-3-yl)quinazoline 
• 286371-65-1 6-(benzyloxy)-4-chloro-7-methoxyquinazoline 
• 31839-21-1 2-amino-5-hydroxy-4-methoxybenzoic acid 

Relevant articles and documents

PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ?-CELL PATHOGENESIS AND TREATING DIABETES

Disulfide-Isomerase A4 (PDIA4) inhibitors and use thereof for inhibiting pancreatic β-cell pathogenesis and treating diabetes are disclosed. Drug candidates that inhibit PDIA4 with IC50 values ranging from 4 μM to 300 nM are identified. The compounds are highly active in augmenting insulin secretion from pancreatic β-cells. The representative compound No. 8 (4,5-dimethoxy-2-propiolamidobenzoic acid), alone or in combination with metformin, is effective in preserving pancreatic β-cell function, treating and/or reversing, returning blood glucose concentration to a normal level in a diabetic.

QUINAZOLINONE COMPOUNDS

New quinazolinone compounds are disclosed, as well as pharmaceutical compositions containing quinazolinones and methods for the treatment of diseases and conditions associated with mitochondrial dysfunction.

Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia

Utilizing structure-based virtual library design and scoring, a novel chimeric series of phosphodiesterase 10A (PDE10A) inhibitors was discovered by synergizing binding site interactions and ADME properties of two chemotypes. Virtual libraries were docked and scored for potential binding ability, followed by visual inspection to prioritize analogs for parallel and directed synthesis. The process yielded highly potent and selective compounds such as 16. New X-ray cocrystal structures enabled rational design of substituents that resulted in the successful optimization of physical properties to produce in vivo activity and to modulate microsomal clearance and permeability.

HETEROAROMATIC QUINOLINE-BASED COMPOUNDS

The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds which are selective inhibitors of PDE10. The invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and the use of such compounds in methods for treating certain central nervous system (CNS) or other disorders. The invention relates also to methods for treating neurodegenerative and psychiatric disorders, for example psychosis and disorders comprising deficient cognition as a symptom.